Patient characteristics of phase 2 FRD
| . | Total (N = 27) . |
|---|---|
| Male/female | 11/16 |
| Median age, y (range) | 64 (51-75) |
| Age >65 y, n (%) | 14 (52) |
| Eastern Cooperative Oncology Group performance status, n (%) | |
| 0 | 16 (59.3) |
| 1 | 11 (40.7) |
| 2 | 0 |
| ISS staging, n (%) | |
| Stage 1 | 5 (18.5) |
| Stage 2 | 5 (18.5) |
| Stage 3 | 5 (18.5) |
| Missing | 12 (44.4) |
| Immunoglobulin subtype, n (%) | |
| IgG | 14 (51.9) |
| IgA | 8 (29.6) |
| IgM | 1 (3.7) |
| None | 4 (14.8) |
| Light-chain subtype, n (%) | |
| k | 18 (66.6) |
| L | 9 (33.3) |
| Fluorescence in situ hybridization, n (%) | |
| Normal | 2 (20) |
| Any abnormality | 22 (81) |
| Any high-risk abnormality | 17 (63) |
| del(17p) | 5 (19) |
| chr 1 amplification | 12 (44) |
| t(4;14) | 4 (15) |
| del(13q) | 5 (18.5) |
| t(11; 14) | 5 (18.5) |
| Median time since diagnosis, y (range) | 4 (1.6-12.4) |
| Prior regimens, median (range) | 3 (1-10) |
| Prior therapy, exposed/refractory, n (%) | |
| Dexamethasone | 27 (100)/19 (70) |
| Thalidomide | 6 (22)/2 (7) |
| Lenalidomide | 27 (100)/22 (81) |
| Pomalidomide | 10 (37)/9 (33) |
| Bortezomib | 27 (100)/14 (52) |
| Carfilzomib | 8 (30)/7 (26) |
| Autologous stem cell transplant | 20 (74) |
| Best response at last treatment, n (%) | |
| CR | 5 (18.5) |
| VGPR | 6 (22.2) |
| PR | 4 (14.8) |
| MR | 1 (3.7) |
| SD | 7 (25.9) |
| PD | 3 (15) |
| Unknown | 1 (5) |
| . | Total (N = 27) . |
|---|---|
| Male/female | 11/16 |
| Median age, y (range) | 64 (51-75) |
| Age >65 y, n (%) | 14 (52) |
| Eastern Cooperative Oncology Group performance status, n (%) | |
| 0 | 16 (59.3) |
| 1 | 11 (40.7) |
| 2 | 0 |
| ISS staging, n (%) | |
| Stage 1 | 5 (18.5) |
| Stage 2 | 5 (18.5) |
| Stage 3 | 5 (18.5) |
| Missing | 12 (44.4) |
| Immunoglobulin subtype, n (%) | |
| IgG | 14 (51.9) |
| IgA | 8 (29.6) |
| IgM | 1 (3.7) |
| None | 4 (14.8) |
| Light-chain subtype, n (%) | |
| k | 18 (66.6) |
| L | 9 (33.3) |
| Fluorescence in situ hybridization, n (%) | |
| Normal | 2 (20) |
| Any abnormality | 22 (81) |
| Any high-risk abnormality | 17 (63) |
| del(17p) | 5 (19) |
| chr 1 amplification | 12 (44) |
| t(4;14) | 4 (15) |
| del(13q) | 5 (18.5) |
| t(11; 14) | 5 (18.5) |
| Median time since diagnosis, y (range) | 4 (1.6-12.4) |
| Prior regimens, median (range) | 3 (1-10) |
| Prior therapy, exposed/refractory, n (%) | |
| Dexamethasone | 27 (100)/19 (70) |
| Thalidomide | 6 (22)/2 (7) |
| Lenalidomide | 27 (100)/22 (81) |
| Pomalidomide | 10 (37)/9 (33) |
| Bortezomib | 27 (100)/14 (52) |
| Carfilzomib | 8 (30)/7 (26) |
| Autologous stem cell transplant | 20 (74) |
| Best response at last treatment, n (%) | |
| CR | 5 (18.5) |
| VGPR | 6 (22.2) |
| PR | 4 (14.8) |
| MR | 1 (3.7) |
| SD | 7 (25.9) |
| PD | 3 (15) |
| Unknown | 1 (5) |